| Literature DB >> 35518160 |
Fatma M Abd El-Mordy1, Mohamed M El-Hamouly2, Magda T Ibrahim3, Gehad Abd El-Rheem4, Omar M Aly5, Adel M Abd El-Kader6,7, Khayrya A Youssif8, Usama Ramadan Abdelmohsen6,9.
Abstract
SARS-CoV-2 is a novel coronavirus that was first identified during the outbreak in Wuhan, China in 2019. It is an acute respiratory illness that can transfer among human beings. Natural products can provide a rich resource for novel antiviral drugs. They can interfere with viral proteins such as viral proteases, polymerases, and entry proteins. Several naturally occurring flavonoids were reported to have antiviral activity against different types of RNA and DNA viruses. A methanolic extract of Manilkara hexandra (Roxb.) Dubard leaves is rich in phenolic compounds, mainly flavonoids. Metabolic profiling of the secondary metabolites of Manilkara hexandra (Roxb.) Dubard leaves methanolic extract (MLME), and bark ethyl acetate (MBEE) extract using LC-HRESIMS resulted in the isolation of 18 compounds belonging to a variety of constituents, among which phenolic compounds, flavones, flavonol glycosides and triterpenes were predominant. Besides, four compounds (I-IV) were isolated and identified as myricetin I, myricitrin II, mearnsitrin III, and mearnsetin-3-O-β-d-rutinoside IV (compound IV is isolated for the first time from genus Manilkara) and dereplicated in a metabolomic study as compounds 3, 5, 6, and 12, respectively. The molecular docking study showed that rutin, myricitrin, mearnsitrin, and quercetin 3-O-β-d-glucoside have strong interaction with SARS-CoV-2 protease with high binding energy of -8.2072, -7.1973, -7.5855, and -7.6750, respectively. Interestingly, the results proved that rutin which is a citrus flavonoid glycoside exhibits the strongest inhibition effect to the SARS-CoV-2 protease enzyme. Consequently, it can contribute to developing an effective antiviral drug lead against the SARS-CoV-2 pandemic. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35518160 PMCID: PMC9056568 DOI: 10.1039/d0ra05679k
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
The LC-HR-ESIMS annotation results of Manilkara hexandra (Roxb.) Dubard leaves and bark extractsa
| No. | Metabolites name | Original source | Chemical class | Mode | MF | RT (min) |
| References |
|---|---|---|---|---|---|---|---|---|
| 1 | Caffeic acid |
| Phenolic acid | + | C9H8O4 | 3.27 | 181.0489 |
|
| 2 | 2,5-Dihydroxy benzoic acid |
| Unsaturated carboxylic acid | + | C7H6O4 | 2.11 | 155.0332 |
|
| 3 | Myricetin I |
| Flavonol | + | C15H10O8 | 2.65 | 319.0441 |
|
| 4 | Myricetin-3- |
| Flavonol | + | C16H12O8 | 2.97 | 333.0608 |
|
| 5 | Myricitrin II |
| Flavonol glycoside | + | C21H20O12 | 4.31 | 465.1026 |
|
| 6 | Mearnsitrin III |
| Flavonol glycoside | + | C22H22O12 | 4.51 | 479.1179 |
|
| 7 | Rutin |
| Flavonol glycoside | + | C27H30O16 | 1.88 | 611.1604 |
|
| 8 | 3′-Methoxy-4′,5,7-trihydroxy flavonol |
| Flavonol | + | C16H12O7 | 3.81 | 317.0653 |
|
| 9 | (+) Catechin |
| Flavan-3-ol | + | C15H14O6 | 2.49 | 291.0787 |
|
| 10 | Quercetin 3- |
| Flavonol glycoside | + | C21H20O12 | 3.38 | 465.1026 |
|
| 11 | Quercetin 3- |
| Flavonol glycoside | + | C21H20O11 | 2.69 | 449.1073 |
|
| 12 | Mearnsetin-3- |
| Flavonol glycoside | + | C28H32O17 | 5.55 | 641.1713 |
|
| 13 | Lupeol-3-acetate |
| Triterpene | + | C32H52O2 | 4.32 | 469.4034 |
|
| 14 | Taraxerone |
| Triterpene | + | C30H48O | 5.62 | 425.3785 |
|
| 15 | 3-Acetyl ursolic acid |
| Triterpene | + | C32H50O4 | 4.04 | 499.3736 |
|
| 16 | Gallocatechin-3- |
| Catechin | + | C22H18O11 | 6.35 | 459.0846 |
|
| 17 | Taxifolin |
| Flavanonol | + | C15H12O7 | 2.86 | 305.0657 |
|
| 18 | Acacetin-7- |
| Flavonoid-7- | + | C28H32O14 | 3.39 | 593.1873 |
|
MF: molecular formula, RT: retention time, min: minute.
Fig. 1Isolated and annotated metabolites from the LC-HRESIMS analysis of Manilkara hexandra (Roxb.) Dubard leaves and bark extracts.
The receptor interaction of and the binding energy scores of the identified compounds, darunavir, and N3 into the N3 binding site in the SARS-CoV-2 main protease
| Compound | dG, kcal mol−1 | E_Conf., kcal mol−1 | E_Place, kcal mol−1 | E_Refine | Receptor |
|---|---|---|---|---|---|
| dG, kcal mol−1 | Amino acid/type of bonding/distance (Å)/binding energy (kcal mol−1) | ||||
| 1 | −5.1104 | −20.7880 | −7.4002 | −8.2307 | Met49/H-donor/3.51/−0.2 |
| 2 | −3.6132 | 31.6316 | −15.5250 | −17.3981 | — |
| 3 (I) | −5.9328 | 31.6316 | −15.5250 | −17.3981 | Met165/H-donor/3.26/−0.4 |
| 4 | −6.2258 | 48.0913 | −15.3310 | −19.7152 | Gln189/Pi-H/4.25/−0.7 |
| 5 (II) | −7.1973 | 122.4130 | −18.0611 | −21.2239 | Met165/H-donor/2.71 and 3.28/−0.3 and −0.2 and Cys145/H-donor/3.68/−0.2 |
| 6 (III) | −7.5855 | 145.0424 | −19.1410 | −26.5002 | Phe140/H-donor/2.93/−1.8 and Gln189/H-donor/3.29/−0.7, Met49/H-donor/3.58/−1.0 |
| 7 | −8.2072 | 211.5644 | −24.6113 | −30.4412 | Asn142/H-donor/3.05/−2.2 and Glu166/H-acceptor 3.53/−0.8 |
| 8 | −5.7864 | 62.4023 | −11.8787 | −17.1581 | Thr190/H-donor/2.25/−0.4 |
| 9 | −5.8134 | 23.4276 | −12.6033 | −18.7543 | His164/H-donor/2.56/−0.3, Met165/H-donor/3.75/−1.6 and Gln189/H-donor/2.47/−0.2 |
| 10 | −7.6750 | 126.5861 | −15.3358 | −25.6531 | Met165/H-donor/3.65/−0.4 and His163/H-acceptor 3.09/−2.3 |
| 11 | −6.9873 | 128. | −21.1809 | −20.2922 | Met165/H-donor/1.75/−1.5, Met49/H-donor/1.95/−0.99, Cys145/H-donor/1.81/−0.51, Gln189/H-donor/2.01/−0.63 and His 163/H-donor/2.4/−0.41 |
| Darunavir | −7.0415 | −26.4826 | −18.8722 | −12.8003 | Cys145/H-donor/3.95/−0.4, Met49/H-donor/3.35/−0.7, Gln189/H-donor/2.2/−0.42 and His41/H-Pi/3.33/−0.1 |
| N3 | −8.4767 | −4.5013 | −18.6098 | −24.9301 | Gln189/H-donor 2.96/−2.3, Glu166/H-donor/3.34/−0.6, Cys145/H-donor/3.99/−2.0, Glu166/H-acceptor 3.48/−0.6, His41/H-Pi/3.71/−0.7 and Asn/Pi-H/4.16/−1.2 |